Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Signing of Definitive Agreement to Acquire Drug Lab 118 (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > also 🚩
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(379)
•••
Comment by Benedictuson Jan 30, 2024 12:46am
121 Views
Post# 35851961

RE:RE:RE:RE:RE:also 🚩

RE:RE:RE:RE:RE:also 🚩
MrMugsy wrote:

Benedictus - from AGM, we know there is confidence on a few fronts.  We also know there are discussions underway.  No details, just that the company is doing what they can in advance.

and ...

with a mountain of OTENA data behind us, we know where we stand with amorphous.  In God's hands now w.r.t. financing.

I wouldn't read much into the last presentation or any general presentation - just not going to move the needle.  They are slow intros for small groups of people.

That being said - something else and something big would be required to make the warrants exciting by February 15th.

In the end, doesn't matter.  Not worth the worry.  We're heading into P2 with a whole understanding of how excitement and nervous wonder cause retail investors to ride that share price coaster one more time.  

This time, money well spent to reposition - derisk and position for much, much more.  Love this game !!!!


Thanks Mugs, appreciate your perspective as always. Should be an exciting year!
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities